Examining Genetic Differences Among People With 21-Hydroxylase Deficiency

21-hydroxylase Deficiency Clinical Trial

Official title:

Modifier Genes in 21-Hydroxylase Deficiency

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00542841
• Other study ID #: RDCRN 5607
• Secondary ID: U54RR019484RR019
• Status: Completed
• Phase: N/A
• First received: October 10, 2007
• Last updated: December 10, 2015
• Start date: August 2007
• Est. completion date: March 2009

Study information

• Verified date: December 2015
• Source: Icahn School of Medicine at Mount Sinai
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Federal Government
• Study type: Interventional

Clinical Trial Summary

Congenital adrenal hyperplasia (CAH) is a genetic disorder that affects the amount of steroids that the body forms. The most common form of CAH is 21-hydroxylase deficiency (21OHD), which leads to cortisol deficiency. This, in turn, causes the development of mature masculine characteristics in newborn, prepubescent, and grown females and in prepubescent males. 21OHD is known to be caused by the mutation of a specific gene. However, symptom severity among people with 21OHD varies, and adults seem to be less affected than children. This study will examine participants' DNA to determine what other genes may affect the severity of 21OHD and may make the disease milder in adults than in children.

Description:

CAH is a genetic steroidogenesis disorder. The most common form, 21OHD, leads to cortisol deficiency and, in turn, an excess of androgen, a hormone that promotes the development and maintenance of male sex characteristics. As a result of this androgen excess, prepubescent males and newborn, prepubescent, and grown females exhibit mature masculine characteristics. The symptoms and severity of 21OHD vary among individuals with the disease and in adults versus children. The reasons for these differences are not yet known. Current therapy for 21OHD consists of administration of glucocorticoids to replace cortisol and suppress excessive pituitary function. With more information about what genes or factors contribute to the severity of 21OHD, researchers may be able to better treat children and adults with the disease. This study will examine participants' DNA to determine what other genes may affect the severity of 21OHD and may make the disease milder in adults than in children.

People interested in participating in this 3-day inpatient study will first undergo a physical exam and provide a blood sample to determine eligibility. Eligible participants will be admitted to the study site in the morning on the first study day. A blood sample will be taken and participants will receive one 10-mg pill of hydrocortisone. Heart rates and blood pressures will be taken every 4 hours throughout the day. In the morning of Day 2, a blood sample will be taken and participants will be asked to urinate in the toilet. After this point and until the end of the study, participants will collect all urine in a jug. On the morning of Day 3, participants will complete urine collection and a blood sample will be taken. Participants will then receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. About 1 hour after this, participants will provide a final blood sample. Participants will receive one last pill of hydrocortisone prior to the end of the study.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 99
• Est. completion date: March 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

• Diagnosis of 21OHD with two "severe" alleles, excluding the A/C656G mutation OR participant consents to genetic testing and a CYP21A2 mutation is identified

• Currently a patient at one of the participating centers

• Currently taking less than 15mg/m² hydrocortisone per day and has been for at least the past 3 months

Exclusion Criteria:

• History of adrenal crisis within 1 year prior to study entry

• Any coexisting condition requiring corticosteroid therapy (e.g., asthma, psoriasis)

• History of removal of both adrenal glands

• History of deficient pituitary gland function

• Current or past use of growth hormone therapy within 3 months prior to study entry

• Serum creatinine level greater than 2 mg/dL

• Systolic blood pressure less than 90 mm Hg

• History of critical illness or surgery that required general anesthesia within 1 month prior to study entry

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• 21-hydroxylase Deficiency
• Adrenal Hyperplasia, Congenital
• Adrenogenital Syndrome

Intervention

Procedure:
• Hydrocortisone withdrawal
This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.

Locations

Country	Name	City	State
Brazil	University of Sao Paolo	Sao Paolo	SP
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Mount Sinai School of Medicine	New York	New York

Sponsors (3)

Lead Sponsor	Collaborator
Maria I. New	National Center for Research Resources (NCRR), Office of Rare Diseases (ORD)

Countries where clinical trial is conducted

United States,  Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Serum 17-hydroxyprogesterone/cortisol ratio		After cosyntropin administration	No
Secondary	Many other serum and urine steroids, metabolites, and precursors		Before and after cosyntropin administration	No